disease 1,233 words KG: ent-dise-32cb96b6
Contents

PSP Epidemiology

Disease Info
Estimated prevalence5-7 per 100,000 population[@psp2023]
Range by region3-10 per 100,000 depending on study methodology
Estimated US populationApproximately 20,000-30,000 individuals
Annual incidence0.5-1.0 per 100,000 person-years
Age-adjusted incidenceIncreases sharply after age 50
Peak incidence60-70 years
Mean age of onset63-68 years
Median age66 years
Range40-85 years
Early-onset PSP<50 years (rare, <5% of cases)
Slight male predominance1.2-1.5:1 ratio
[MAPT](/proteins/tau) H1 haplotypeStrongest genetic risk factor[@mapt2022]
DatabasesOMIMOrphanetClinicalTrialsPubMed

No AI portrait yet

Knowledge Graph

Agent Input

💡 Improve this page

🌐 Cross-references

OMIMMeSHWikipedia

Related Hypotheses (1)

Blocking AGE-RAGE Signaling in Enteric Glia to Prevent Neuro
Score: 0.61

Related Analyses (5)

4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · completed
4R-tau strain-specific spreading patterns in PSP vs CBD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed

Related Experiments (30)

Tau Pathology Initiation Zone Identification
clinical · proposed · Score: 0.40
Levodopa Response Determinants in PSP — Biomarker-Guided Pre
clinical · proposed · Score: 0.40
4R-Tau Targeting Therapies for PSP and CBS
clinical · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.